Avidity NanoMedicines is advancing a new class of drug candidates, antibody-siRNA complexes (ARCs™), which draw on the best features of both antibody-drug conjugates and nucleic acid-based medicines and which utilize nano-scale self-assembly to create a transformative approach to the treatment of cancer and other serious diseases. Although nucleic acid-based therapeutics have demonstrated success in targeting the liver, systemic bioavailability remains a challenge. Our technology combines the potency and specificity of biologics with nanoparticle technology and precise molecular targeting to create a platform that can be tailored to specific tumors.